| Not Yet Recruiting | BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Brea HR+/HER2- Breast Cancer | Phase 3 | 2026-05-11 |
| Not Yet Recruiting | A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2026-04-30 |
| Recruiting | A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Dise Skin Diseases | Phase 1 | 2026-03-19 |
| Recruiting | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acal Chronic Lymphocytic Leukemia | Phase 3 | 2026-01-22 |
| Recruiting | An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Adv Breast Cancer, Advanced Solid Tumor | Phase 1 | 2025-12-11 |
| Recruiting | A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2025-12-11 |
| Recruiting | A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Adv Solid Tumors, Advanced Solid Tumor | Phase 1 | 2025-11-10 |
| Completed | A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Contain Healthy Volunteers | Phase 1 | 2025-09-24 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Ref Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | 2025-09-04 |
| Recruiting | A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Ch Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 3 | 2025-08-27 |
| Recruiting | A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituxi Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | 2025-06-11 |
| Recruiting | A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lympho Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | 2025-05-29 |
| Recruiting | A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Sm CLL, Chronic Lymphocytic Leukemia | Phase 3 | 2025-04-10 |
| Recruiting | A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zan Mantle Cell Lymphoma, B Cell Lymphoma | Phase 3 | 2025-03-05 |
| Recruiting | BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growt Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer | Phase 1 | 2025-02-04 |
| Recruiting | A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug C Advanced Solid Tumor | Phase 1 | 2024-12-09 |
| Active Not Recruiting | A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lu Non-Small Cell Lung Cancer, Lung Cancer, NSCLC | Phase 1 | 2024-12-05 |
| Recruiting | A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants B-cell Malignancy, Relapsed Cancer, Refractory Cancer | Phase 1 / Phase 2 | 2024-11-27 |
| Active Not Recruiting | A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With P Chronic Lymphocytic Leukemia | Phase 2 | 2024-11-14 |
| Active Not Recruiting | An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors Advanced or Metastatic MTAP-deleted Solid Tumors | Phase 1 | 2024-10-12 |
| Recruiting | An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participa Advanced Solid Tumor | Phase 1 | 2024-10-11 |
| Recruiting | A Study of BG-C477 in Participants With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2024-10-03 |
| Recruiting | A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Partic Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer | Phase 1 | 2024-07-23 |
| Active Not Recruiting | A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors Solid Tumor | Phase 1 | 2024-07-16 |
| Active Not Recruiting | A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced So Advanced Solid Tumor | Phase 1 | 2024-07-08 |
| Recruiting | Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patie Advanced Solid Tumor | Phase 1 | 2024-04-12 |
| Recruiting | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Soli Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer | Phase 1 | 2023-12-01 |
| Active Not Recruiting | Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Pa CLL | Phase 3 | 2023-11-11 |
| Active Not Recruiting | A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination Wit Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory | Phase 2 | 2023-10-23 |
| Recruiting | A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Advanced Solid Tumor, Solid Tumor | Phase 1 | 2023-09-21 |
| Active Not Recruiting | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Chronic Lymphocytic Leukemia | Phase 1 | 2023-06-20 |
| Active Not Recruiting | A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy Primary Membranous Nephropathy | Phase 2 / Phase 3 | 2023-04-17 |
| Recruiting | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Pl Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | 2021-09-16 |
| Recruiting | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | 2021-09-13 |
| Active Not Recruiting | Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies Mature B-Cell Malignancies | Phase 1 | 2020-03-24 |
| Active Not Recruiting | Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies Advanced Malignancies | Phase 3 | 2019-12-19 |